HC Wainwright Cuts Earnings Estimates for Ocular Therapeutix

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for Ocular Therapeutix to (0.39), indicating a decrease from the previous estimate of (0.37), while maintaining a "Buy" rating and a $15.00 target price.
• The company reported a Q2 2025 EPS of (0.39), which was $0.04 lower than analysts' expectations, despite exceeding revenue estimates of $13.46 million against an expected $13.12 million.
• Ocular Therapeutix has a consensus "Buy" rating from analysts, with an average price target of $17.17 as several research firms adjust their price objectives for the stock.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for Ocular Therapeutix in a report released on Wednesday, August 6th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will earn ($0.39) per share for the quarter, down from their prior forecast of ($0.37). HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.53) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.49) EPS.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The business had revenue of $13.46 million for the quarter, compared to analysts' expectations of $13.12 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. The business's quarterly revenue was down 17.7% on a year-over-year basis.

Several other research firms have also issued reports on OCUL. Scotiabank cut their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Wednesday. Needham & Company LLC upped their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $17.20.

Ocular Therapeutix Trading Down 0.7%

NASDAQ OCUL traded down $0.09 during trading on Friday, hitting $12.21. 2,019,053 shares of the company's stock traded hands, compared to its average volume of 2,064,826. The stock has a fifty day moving average of $10.17 and a two-hundred day moving average of $8.38. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.14. Ocular Therapeutix has a 12-month low of $5.78 and a 12-month high of $12.65. The firm has a market cap of $2.12 billion, a P/E ratio of -9.54 and a beta of 1.49.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently modified their holdings of OCUL. Deep Track Capital LP lifted its holdings in Ocular Therapeutix by 0.9% in the fourth quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock worth $109,622,000 after buying an additional 114,822 shares during the period. Vanguard Group Inc. lifted its holdings in Ocular Therapeutix by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after buying an additional 99,730 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Ocular Therapeutix by 44.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock worth $38,116,000 after buying an additional 1,600,000 shares during the period. Point72 Asset Management L.P. lifted its holdings in Ocular Therapeutix by 43.9% in the fourth quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after buying an additional 895,304 shares during the period. Finally, Deltec Asset Management LLC lifted its holdings in Ocular Therapeutix by 2.9% in the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company's stock worth $25,937,000 after buying an additional 78,519 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,219 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the sale, the insider directly owned 3,499,099 shares in the company, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 29,079 shares of company stock worth $208,739 in the last ninety days. Corporate insiders own 2.30% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.